CurrentUnitedHealthcarePolicy CS079NJ.O

Minimally Invasive Procedures for Gastric and Esophageal Diseases (for New Jersey Only)

UnitedHealthcare medical policy (New Jersey only) defining coverage positions for minimally invasive endoscopic and laparoscopic procedures for esophageal and gastric diseases (POEM, Z-POEM, G-POEM, GERD endoluminal therapies, LINX, FLIP, etc.), including definitions, rationale, evidence summary, and applicable CPT procedure codes (reference list). This is Part 1 of 4; contains coverage rationale, definitions, descriptions, evidence review, and an applicable codes list.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases (for New Jersey Only)

Policy CodePolicy CS079NJ.O

Change TypeClarification (POEM coverage) + Evidence/reference updates

Effective DateDec 1, 2024

Next Review Date

Key ActionThis medical policy only applies to the state of New Jersey; providers must ensure policy applicability for New Jersey members.

SourceLink

POLICY UPDATE CHANGES

Clarified that POEM is proven and medically necessary for Achalasia and Diffuse Esophageal Spasm.

Updated Clinical Evidence and References sections to reflect current information.

2Indications covered (POEM)

multipleProcedures unproven/not medically necessary

7CPT codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

G-POEM pooled symptomatic response

insufficientEvidence insufficient for polymer injections and FLIP

Coverage Summary

UnitedHealthcare (New Jersey only) policy CS079NJ.O defines coverage positions for minimally invasive endoscopic and laparoscopic procedures for esophageal and gastric diseases (including POEM, Z-POEM, G-POEM, endoluminal GERD therapies, LINX/MSA, and FLIP). Effective date: 2024-12-01. Coverage stance is mixed (some indications covered, others considered unproven/not medically necessary). This document is Part 1 of 4 of the policy series.

Primary covered indications in this part: POEM is proven and medically necessary for Achalasia and Diffuse Esophageal Spasm. Major categories explicitly described as not covered or unproven in this part include G-POEM for gastroparesis (unproven/not medically necessary), routine diagnostic or outcome use of FLIP/EndoFLIP (unproven), polymer injection/bulking implants and various endoluminal GERD therapies including some injection/implantation techniques and unapproved devices (e.g., GERDx) as unproven/not medically necessary.

Key policy facts (brief)

Policy numberCS079NJ.O

Payer (state applicability)UnitedHealthcare (New Jersey only)

Effective date2024-12-01

Covered indications (POEM)Achalasia; Diffuse Esophageal Spasm

Primary not medically necessary (examples)G-POEM for gastroparesis; FLIP for diagnosis of Achalasia; polymer injections/implantation for GERD; LINX (MSA) considered unproven/conditional

NotesPart 1 of 4

Medical-Necessity Criteria

Coverage Rationale

Covered when ALL of the following statements apply or NOT covered when specific conditions apply:

ALL of the following

POEM Covered Indications: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Achalasia.
POEM Covered Indications: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Diffuse Esophageal Spasm.

POEM Not Covered for Other Indications: POEM is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy.

Evidence Summary & Technology-Specific Conclusions

Evidence summary and implied coverage considerations

Summaries of study findings and limitations for each procedure category (useful for determining medical necessity):

ANY of the following

G-POEM: Gastric Peroral Endoscopic Myotomy (G-POEM) — multiple systematic reviews and case series report symptom improvement (GCSI reductions, improved 4-hour gastric emptying scintigraphy) in refractory gastroparesis with pooled response rates (~76%) but studies limited by retrospective designs, lack of control groups, single-center tertiary settings, subjective measures, small sample sizes, and limited long-term outcomes.
Stretta: Radiofrequency Energy (Stretta System) — mixed evidence: some systematic reviews/meta-analyses and case series report improved GERD symptom scores, quality-of-life, and decreased PPI use up to 5 years; a high-quality 2020 randomized double-blind sham-controlled trial (Zerbib et al.) found no significant benefit vs sham at 24 and 48 weeks. Overall evidence considered low to uncertain; procedural safety appears acceptable but efficacy vs standard surgical care is uncertain.

Provider Actions & Documentation Requirements

Documentation Required

State applicability

This policy applies only to UnitedHealthcare members covered under New Jersey state plans. Providers should confirm member eligibility and applicable state or contract requirements prior to submission. For services rendered to members outside New Jersey, refer to the applicable UnitedHealthcare policy for that state or the national policy.

Applies exclusively to New Jersey members and New Jersey contractual requirements.

Documentation Required

Indication documentation for POEM

When requesting coverage for per oral endoscopic myotomy (POEM), documentation must support a diagnosis of Achalasia or Diffuse Esophageal Spasm. Clinical records should include symptom history, objective testing results (e.g., manometry), and documentation that less invasive therapies have been considered or attempted when appropriate.

Affected CPT code: 43497
Diagnosis documentation supporting Achalasia or Diffuse Esophageal Spasm (e.g., high-resolution esophageal manometry results).

Coding (Reference CPT & Informational Codes)

Reference CPT codes mentionedCPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43999	Unlisted procedure, stomach.

Device & procedure informational listmixed

No codes listed

Coding note: the listed CPT/HCPCS codes in the Applicable Codes section are provided for reference only and do not by themselves determine coverage or reimbursement. Benefit coverage is subject to federal, state, and contractual requirements and medical necessity/prior authorization rules. See provider_actions documentation callouts for required clinical documentation when billing procedures that are described as investigational, unproven, or not medically necessary (for example, documentation of indication for POEM or acknowledgement of investigational status for G-POEM, FLIP, LINX, GERDx).

Definitions

Glossary

Achalasia: A primary esophageal motor disorder with impaired relaxation of the esophagogastric junction and loss of organized peristalsis.

Diffuse Esophageal Spasm: A rare motility disorder with simultaneous, uncoordinated, or rapidly propagated contractions accompanied by dysphagia.

GERD (Gastroesophageal Reflux Disease): Condition in which the lower esophageal sphincter relaxes or weakens allowing reflux of stomach acid into the esophagus.

Gastroparesis: Chronic delayed gastric emptying in the absence of mechanical obstruction.

G-POEM: Gastric per-oral endoscopic myotomy, an endoscopic pyloric myotomy technique proposed for refractory gastroparesis.

Stretta: Endoscopic radiofrequency energy delivery to tissue around the lower esophageal sphincter intended to treat GERD.

TIF / EsophyX: Transoral incisionless fundoplication performed with the EsophyX device (endoluminal full-thickness plication for GERD).

MUSE: Medigus Ultrasonic Surgical Endostapler system for transoral partial fundoplication (TIF-like stapling device).

GERD-HRQL: Gastroesophageal Reflux Disease Health-Related Quality of Life questionnaire (validated symptom score).

GCSI: Gastroparesis Cardinal Symptom Index (symptom severity instrument for gastroparesis).

MSA: Magnetic Sphincter Augmentation (LINX Reflux Management System) — an implantable magnetic ring to augment the LES.

Evidence & Outcome Thresholds

Study/Source	Key finding
Werner et al. 2019 (RCT POEM vs LHM)
POEM non-inferior to LHM+fundoplication at 2 years; clinical success POEM 83.0% vs LHM 81.7% (difference 1.4 pts); higher reflux with POEM
G-POEM RCT Martinek 2022
Randomized sham-controlled pilot: G-POEM superior to sham at 6 months (15/21 vs 4/20 success); some serious AEs; small trial, limited long-term data
G-POEM pooled response 76%
Systematic reviews/meta-analysis (Mohan et al. 2020): pooled symptom response ≈76%; mean GCSI improved from ~3.4 to ~1.8; studies mostly retrospective, limited controls
Stretta Zerbib 2020 (RCT)
Randomized double-blind sham-controlled trial: no significant benefit vs sham at 24 and 48 weeks
Stretta Fass 2017 (meta-analysis)
Systematic review/meta-analysis: pooled improvements in HRQL, heartburn scores and reduced PPI use (49% remained on PPI); evidence largely low quality and observational
TIF outcomes
Multiple RCTs/meta-analyses: short-term symptom control and reduced PPI use (~75% at 5 years in some cohorts); durability declines over time, long-term objective reflux control variable
MSA pooled outcomes
Meta-analyses: high rates of PPI withdrawal (~87%), GERD-HRQL improvement (~88%), AET normalization ~75%; but postoperative dysphagia common (~29%), rare device erosion (0.3% at 4 yrs)
FLIP evidence conclusion
EndoFLIP/FLIP: evidence insufficient for routine diagnostic or procedural guidance use; utility unproven, more studies needed
FDA approvals note
Device approvals documented: Stretta (2000), EndoCinch (2001), EsophyX2 cleared (2009), MUSE (2015), EndoFLIP (2017), LINX PMA (2012)

Reported thresholds / objective examples

GCSI improvement (example thresholds)Mean reductions reported (example: from 3.4 to 1.8); success often defined as ≥1 point decrease in average total GCSI or ≥50% reduction in total GCSI in some trials

4-hour GES exampleExample reported improvement: mean 4-h GES improved from 49.9% to 20.6%

GERD-HRQL improvement threshold≥50% improvement frequently used as a primary outcome in multiple endoscopic fundoplication/TIF/MUSE studies

Abnormal esophageal acid exposure examplesBaseline percent time pH <4 often used (eg, ≥4%); post-procedure percent time pH <4 decreases used as objective endpoint

Revision History

2024-12-01material_changeLatest

Policy language added clarifying that POEM is proven and medically necessary for treating Achalasia and Diffuse Esophageal Spasm, and that POEM is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula).

2024-12-01supporting_information_update

Supporting information and references were updated; previous policy version CS079NJ.N archived.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases (for New Jersey Only)

Policy CodePolicy CS079NJ.O

Change TypeClarification (POEM coverage) + Evidence/reference updates

Effective DateDec 1, 2024

Next Review Date

Key ActionThis medical policy only applies to the state of New Jersey; providers must ensure policy applicability for New Jersey members.

SourceLink

On This Page

G-POEM: Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of Gastroparesis.

GERD Endoluminal Therapies: The following are unproven and not medically necessary for treating Gastroesophageal Reflux Disease (GERD) due to insufficient evidence of efficacy: endoscopic therapies; injection or implantation techniques; LINX Reflux Management System.

GERD Endoluminal Therapies: Endoluminal therapy with GERDx™ is investigational, unproven, and not medically necessary for treating GERD as it has not received FDA approval.

FLIP / Functional Lumen Imaging Probe: Functional lumen imaging probe (FLIP) technology is unproven and not medically necessary for diagnosing Achalasia.

Endoscopic Plication/Suturing: Endoscopic Plication / Suturing (including TIF, EsophyX, EndoCinch, EFTP, GERDx, MUSE) — multiple RCTs, systematic reviews and observational studies show improvements in GERD symptom scores and reduced PPI use in selected patients; durability and long-term effectiveness variable across studies; many studies limited by small size, lack of long-term follow-up, heterogeneity, and limited direct comparisons to laparoscopic Nissen fundoplication (LNF).

ANY of the following

TIF/EsophyX: Transoral Incisionless Fundoplication (TIF/EsophyX): Short-term patient satisfaction and symptom control comparable to alternatives; long-term efficacy decreases with time and many patients resume PPI; randomized trials needed.
Effective 12/01/2024
Polymer Injections: Polymer injection/implantation techniques (Plexiglas, Durasphere): Evidence insufficient to consider proven effective and safe; additional randomized studies warranted.
Small case series show some short-term reduction in PPI use but limitations include small sample sizes and lack of controls.
LINX / MSA: LINX Reflux Management System (Magnetic Sphincter Augmentation - MSA): Evidence shows short-term symptom relief, quality-of-life improvement, high rates of PPI discontinuation for many patients; concerns about postoperative dysphagia, need for dilation, rare device erosion and device removal; long-term safety and durability remain uncertain and additional RCTs needed.
Multiple systematic reviews, meta-analyses, RCT(s), cohort studies cited; Effective 12/01/2024 note present
FLIP: Functional Lumen Imaging Probe (FLIP/EndoFLIP): Evidence insufficient for routine use for diagnosis, procedure guidance, or outcome evaluation in esophageal/gastric disorders; more research needed.
Systematic reviews and technology assessments (Hayes, ECRI) conclude inconclusive/insufficient evidence.

ALL of the following

POEM Covered Indications: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Achalasia
POEM Covered Indications: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Diffuse Esophageal Spasm
POEM not covered for other indications: POEM is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy

Technology-specific coverage conclusions (evidence-based summaries)

Summarized coverage stance based on evidence presented in this part:

TIF/EsophyX: Transoral Incisionless Fundoplication (TIF/EsophyX): Short-term patient satisfaction and symptom control comparable to alternatives; long-term efficacy decreases with time and many patients resume PPI; randomized trials needed.

Effective 12/01/2024

Polymer injections: Polymer injection/implantation techniques (Plexiglas, Durasphere): Evidence insufficient to consider proven effective and safe; additional randomized studies warranted.

Small case series show some short-term reduction in PPI use but limitations include small sample sizes and lack of controls.

LINX / MSA: LINX Reflux Management System (Magnetic Sphincter Augmentation - MSA): Evidence shows short-term symptom relief, quality-of-life improvement, high rates of PPI discontinuation for many patients; concerns about postoperative dysphagia, need for dilation, rare device erosion and device removal; long-term safety and durability remain uncertain and additional RCTs needed.

Multiple systematic reviews, meta-analyses, RCT(s), cohort studies cited; Effective 12/01/2024 note present

FLIP: Functional Lumen Imaging Probe (FLIP/EndoFLIP): Evidence insufficient for routine use for diagnosis, procedure guidance, or outcome evaluation in esophageal/gastric disorders; more research needed.

Systematic reviews and technology assessments (Hayes, ECRI) conclude inconclusive/insufficient evidence.

Definitions context: the policy provides concise clinical and device/technique definitions so readers understand referenced conditions and procedures. Examples include definitions and context for POEM, G-POEM, FLIP/EndoFLIP, and key endoluminal GERD procedures such as TIF/EsophyX, Stretta, and MSA (LINX). Full formal definitions and device indications appear in the Definitions section of the policy.

Documentation Required

Not medically necessary documentation

Document clearly when a requested procedure is considered investigational, unproven, or not medically necessary per this policy. Include rationale and supporting evidence if the provider believes the intervention is medically necessary despite policy statements.

Common codes associated with procedures considered investigational or not medically necessary: 43257, 43284, 43499, 43999

Documentation Required

Patient selection documentation

Patient selection must be documented to demonstrate medical necessity. For GERD-related procedures, document prior conservative therapy (including a trial of optimized PPI therapy) and objective testing. For anti-reflux device or surgical options, confirm absence of contraindications such as advanced esophagitis or large hiatal hernia beyond device limits.

Document prior conservative therapy (e.g., optimized PPI regimen and persistent symptoms despite therapy).
Objective testing examples: upper endoscopy (EGD), ambulatory pH monitoring (or DeMeester score), esophageal manometry, hiatal hernia size assessment.
Symptom and severity measures (e.g., GERD symptom profile, frequency of regurgitation).

Documentation Required

Outcome measurement documentation

Record baseline and follow-up outcome measures to support clinical benefit. Use validated symptom instruments and objective testing to document treatment response and durability, and record ongoing PPI use.

Validated symptom scores: GCSI (Gastroparesis Cardinal Symptom Index), GERD-HRQL (GERD-Health Related Quality of Life).
Objective measures: Gastric emptying study (GES) for gastroparesis, high-resolution esophageal manometry, and ambulatory pH testing (including DeMeester score).
Medication use: ongoing PPI dosing and frequency.

Prior Authorization

Prior authorization and review may be required

Prior authorization or individual case review may be required for several minimally invasive procedures. Providers should obtain PA or confirmation of coverage when planning interventions where review is commonly required or where policy indicates limited coverage.

Procedures that may require prior authorization or individual review: Transoral incisionless fundoplication (TIF), Magnetic Sphincter Augmentation (MSA; e.g., LINX), FLIP (when used therapeutically or as part of a procedural decision), polymer/poly(methyl methacrylate) injection therapies.
Selection criteria to include with PA requests: PPI-refractory regurgitation or persistent symptoms despite optimized medical therapy; hiatal hernia size within device-specific limits (document measured size); absence of advanced/LA grade C–D esophagitis or Barrett’s with high-grade dysplasia; confirmatory diagnostic testing such as manometry and pH testing as indicated.
Confirmatory diagnostic testing prior to MSA: document objective reflux (ambulatory pH testing) and anatomy (EGD/hiatal hernia assessment) and that conservative therapy has failed or is contraindicated.

Denial Risk

Risk of non-coverage

Procedures or indications with insufficient or conflicting evidence are at risk for denial. If pursuing coverage for such services, include comprehensive documentation of medical necessity and relevant diagnostic/therapeutic history to support the request.

Procedures at higher risk of non-coverage include polymer injection/implantation techniques, diagnostic use of FLIP when intended as a standalone definitive diagnostic test for Achalasia, G-POEM for gastroparesis (per policy), and other techniques explicitly listed as investigational or unproven in this policy.
If requesting coverage for an intervention with limited evidence, supply detailed clinical rationale, prior treatments, objective testing results, and any supporting literature or specialist consultation notes.

Documentation Required

Use evidence & guidelines in coverage decisions

Coverage determinations should be made in the context of federal, state, and contractual requirements and in accordance with UnitedHealthcare policy. Clinicians and reviewers may also consider clinical guidelines (e.g., ACG, ASGE), InterQual criteria, and individualized clinical judgment when evaluating requests.

FLIP / EndoFLIP: Functional Lumen Imaging Probe (impedance planimetry device to measure esophagogastric junction distensibility index and dimensions).

POEM: Per oral endoscopic myotomy — an endoscopic submucosal tunnel myotomy to treat achalasia and certain spastic esophageal disorders.